StockReport.com is a 7:00 PM newsletter with a pertinent stock report every day, plus the lates market news.
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.
The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. In parallel, Crinetics is advancing CRN04894, a vasopressin V2 receptor antagonist for the management of hyponatremia, and CRN04912, an oral ghrelin receptor inverse agonist being developed for congenital hyperinsulinism. These programs reflect Crinetics’ strategy to build a focused pipeline addressing multiple rare endocrine disorders with high unmet medical need.
Founded in 2013 and headquartered in San Diego, California, Crinetics Pharmaceuticals operates with an organizational structure designed to support both in-house discovery and external collaborations. The company engages with academic research centers and clinical investigators across North America and Europe to advance its clinical studies and to explore additional indications for its pipeline candidates. Crinetics’ integrated approach combines medicinal chemistry, translational biology and clinical development expertise under one roof, with the goal of accelerating the path from laboratory to patient care.
As a publicly traded company on the NASDAQ under the ticker CRNX, Crinetics maintains a governance framework led by a board of directors and an executive leadership team with deep experience in endocrinology, drug development and regulatory affairs. The company continues to invest in expanding its pipeline and strengthening its scientific capabilities to bring new treatment options to patients with rare hormonal disorders.
The economic picture hasn't looked very rosy: Hiring has been sluggish. Consumers have been dealing with soaring meat prices. Layoffs are rippling through companies.But despite those concerns, shoppers hit the stores in full strength on Black Friday, with some even sipping champagne as they searched...
Canadian Prime Minister Mark Carney and the premier of Canada’s oil rich province of Alberta have agreed to work toward building a pipeline to the Pacific Coast to diversify the country’s oil exports beyond the United States, in a move that has caused turmoil in Carney’s inner circle
Shares in Europe are mixed following gains in most Asian markets. The futures for the S&P 500 and the Dow Jones Industrial Average were nearly unchanged ahead of Thursday's Thanksgiving holiday.In early European trading, Germany's DAX climbed 0.2% to 23,781.53. Britain's FTSE 100 slid 0.2% to 9,...
U.S. stocks closed broadly higher Wednesday, extending Wall Street’s recent winning streak to a fourth straight day. The S&P 500 rose 0.7%, the Dow Jones Industrial Average gained 0.7% and the Nasdaq composite added 0.8%. Solid gains for technology companies led the rally, although the gains wer...